批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2016/11/29 |
SUPPL-11(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/10/16 |
SUPPL-10(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/10/16 |
SUPPL-2(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/10/16 |
SUPPL-1(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/03/02 |
SUPPL-9(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2012/03/02 |
SUPPL-8(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2010/08/11 |
SUPPL-6(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2003/10/27 |
SUPPL-5(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2001/09/07 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2000/07/21 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1998/02/10 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:NARATRIPTAN HYDROCHLORIDE 剂型/给药途径:TABLET;ORAL 规格:EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020763 |
001 |
NDA |
AMERGE |
NARATRIPTAN HYDROCHLORIDE |
TABLET;ORAL |
EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
Discontinued |
Yes |
No |
AB |
1998/02/10
|
GLAXOSMITHKLINE LLC |
活性成分:NARATRIPTAN HYDROCHLORIDE 剂型/给药途径:TABLET;ORAL 规格:EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020763 |
002 |
NDA |
AMERGE |
NARATRIPTAN HYDROCHLORIDE |
TABLET;ORAL |
EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
Discontinued |
Yes |
No |
AB |
1998/02/10
|
GLAXOSMITHKLINE LLC |